Daniel D. Burton - Jun 7, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role
Chief Executive Officer, Director
Signature
/s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Jun 7, 2021
Transactions value $
-$2,930,456
Form type
4
Date filed
6/9/2021, 09:17 PM
Previous filing
Jun 7, 2021
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCAT Common Stock Options Exercise $561K +35.4K +12.52% $15.84 319K Jun 7, 2021 Direct
transaction HCAT Common Stock Sale -$597K -11.1K -3.49% $53.72 308K Jun 7, 2021 Direct F1, F2
transaction HCAT Common Stock Sale -$163K -2.99K -0.97% $54.54 305K Jun 7, 2021 Direct F1, F3
transaction HCAT Common Stock Sale -$2.15M -38.5K -12.63% $55.80 266K Jun 7, 2021 Direct F1, F4
transaction HCAT Common Stock Sale -$586K -10.4K -3.92% $56.23 256K Jun 7, 2021 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCAT Stock Option (Right to Buy) Options Exercise $0 -35.4K -21.48% $0.00 130K Jun 7, 2021 Common Stock 35.4K $15.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1.
F2 Represents the weighted average sale price of the shares sold ranging from $53.08 to $54.07 per share, inclusive.
F3 Represents the weighted average sale price of the shares sold ranging from $54.10 to $55.04 per share, inclusive.
F4 Represents the weighted average sale price of the shares sold ranging from $55.14 to $56.13 per share, inclusive.
F5 Represents the weighted average sale price of the shares sold ranging from $56.14 to $56.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) though (5).
F6 25% of the 299,748 shares underlying the option vested in an annual installment on February 5, 2020 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.